诊断学理论与实践 ›› 2019, Vol. 18 ›› Issue (04): 402-411.doi: 10.16150/j.1671-2870.2019.04.005
杨迟晖1,2, 张晶1, 孟磊俊3, 宫丽平4, 常庆5, 张泓3(), 曾乃燕1()
收稿日期:
2018-10-22
出版日期:
2019-08-25
发布日期:
2019-08-25
通讯作者:
张泓,曾乃燕
E-mail:zhanghong3010@126.com;zengny@shsmu.edu.cn
基金资助:
YANG Chihui1,2, ZHANG Jing1, MENG Leijun3, GONG Liping4, CHANG Qing5, ZHANG Hong3(), ZENG Naiyan1()
Received:
2018-10-22
Online:
2019-08-25
Published:
2019-08-25
Contact:
ZHANG Hong,ZENG Naiyan
E-mail:zhanghong3010@126.com;zengny@shsmu.edu.cn
摘要:
目的: 通过对比分析乳头状甲状腺癌(papillary thyroid cancer,PTC)和癌旁组织中NF-κB信号通路相关基因的差异表达,以及52个实体瘤相关基因的突变情况,鉴定与PTC临床诊断治疗相关的肿瘤特异性分子靶点。方法: 分别提取20例PTC石蜡样本的癌与癌旁组织的RNA及DNA,运用定量反转录聚合酶链式反应(quantitative reverse transcription PCR,qRT-PCR)分析NF-κB信号通路目的基因CD44、BCL2、CCND2、c-FLIP、IκBα、A20及ABINs的RNA水平表达,并用免疫组化方法进行蛋白水平表达验证。同时利用靶向二代测序(next generation sequencing,NGS)对其中5例随访复发病例的肿瘤相关基因的突变情况进行全面分析筛选。结果: PTC癌组织中CD44和CCND2基因在RNA和蛋白水平的表达均显著高于癌旁组织。在有淋巴结转移和无淋巴结转移的PTC间,各NF-κB目的基因的表达量差异均无统计学意义。在基因水平,ALK、BRAF、FGFR3/4、KIT、MYC及MAPK信号通路的HRAS、KRAS、NRAS及RET是PTC中的高频突变基因。有2例病例分别含35个和40个突变基因,存在很大肿瘤负荷,结合临床数据发现均为术后复发患者。常见的BRAF V600E突变并非都是体细胞突变(64%),也可为胚系突变(29%);用NGS和qPCR同时检测验证V600E时,2种方法检出结果的相符率达80%。结论: CD44和CCND2基因在乳头状甲状腺癌癌组织中高表达,BRAF、RAS、FGFRs、KIT和MYC等基因的肿瘤特异性突变可能作为临床上对PTC患者实施个体化治疗所需的分子靶点。NGS和qPCR技术对BRAF V600E检测具有很高平行性,联合应用可提高检出率。
中图分类号:
杨迟晖, 张晶, 孟磊俊, 宫丽平, 常庆, 张泓, 曾乃燕. 对乳头状甲状腺癌临床分子靶标的筛选[J]. 诊断学理论与实践, 2019, 18(04): 402-411.
YANG Chihui, ZHANG Jing, MENG Leijun, GONG Liping, CHANG Qing, ZHANG Hong, ZENG Naiyan. Screening and identification of clinical molecular targets in papillary thyroid cancers[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(04): 402-411.
表2
实时荧光定量PCR的引物序列
基因 | 引物 | 序列(5'→3') | 扩增子长 度(bp) |
---|---|---|---|
A20 | 正向 反向 | AGGTTCCAGAACACCATTCC GGCTCGATCTCAGTTGCTC | 151 |
ABIN-1 | 正向 反向 | GAAGCAAGTGGAGAAGCTGC CTCTCCTGAGGCCTTTGCT | 127 |
ABIN-2 | 正向 反向 | GCAGATTCTCGCTTACAAGGA TCCTGTCTCCAGGACACCT | 126 |
ABIN-3 | 正向 反向 | CGCCTCAATAAGGCTCTTCA GCACCTGCTGCTTCAGAAC | 133 |
BCL2 | 正向 反向 | GATAACGGAGGCTGGGATG AGCCAGGAGAAATCAAACAGAG | 74 |
CCND2 | 正向 反向 | CTGGCCTCCAAACTCAAAGAG GCACCACCAGTTCCCACTC | 109 |
CD44 | 正向 反向 | CAGCTCCACCTGAAGAAGATTG GGTGCCATCACGGTTAACAA | 95 |
c-FLIP | 正向 反向 | GACCTGCTCAAACGTATCTTGAAG CTCTGCCATCAGCACTCTATAGTC | 102 |
IRF4 | 正向 反向 | CTTTGAGGAACTGGTTGAGCG GCTGCTTGGCTCCTTTTTTG | 98 |
表3
免疫组化分析检测CD44、Cyclin D2和BCL2蛋白在PTC和NAT中的表达
病例号 | CD44 | Cyclin D2 | BCL2 | |||||
---|---|---|---|---|---|---|---|---|
NAT | PTC | NAT | PTC | NAT | PTC | |||
2 | + | - | + | - | ++/+++ | + | ||
+ | + | ++/+++ | +/++ | |||||
9 | + | +++ | -/+ | ++/+++ | ++/- | ++/+/- | ||
10 | + | +++ | + | ++/+++ | +/- | ++/+++ | ||
11 | + | +++ | + | ++/+++ | ++/+++ | ++/+++ | ||
12 | + | ++ | + | ++/+++ | ++/+++ | ++/+++ | ||
13 | + | ++/+++ | + | ++/+++ | ++/+++ | ++/+++ | ||
14 | + | +++ | + | ++ | ++/+++ | ++/+++ | ||
15 | + | +++ | + | ++ | ++/+++ | ++/+++ | ||
16 | + | +++ | + | +++ | ++/+++ | ++/+++ | ||
17 | + | ++ | + | +++ | ++/+++ | ++/+++ | ||
18 | + | +++ | + | +++ | ++/+++ | -/+ |
表4
靶向NGS和qPCR对比分析PTC和NAT中的BRAF V600E基因突变情况
病例号 | 组织 | 组织类型 | qPCR检测 BRAF V600 | NGS检测 BRAF V600 | 突变类型 | 病例号 | 组织 | 组织类型 | qPCR检测 BRAF V600 | NGS检测 BRAF V600 | 突变类型 |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 甲状腺 | NAT | 谷氨酸 | 谷氨酸# | GM | 11 | 甲状腺 | PTC | 谷氨酸 | - | SM |
PTC | 谷氨酸 | 谷氨酸# | 淋巴结 | NAT | 缬氨酸 | - | |||||
3 | 甲状腺 | NAT | 缬氨酸 | - | SM | PTC | 谷氨酸 | - | |||
PTC | 谷氨酸 | - | 12 | 甲状腺 | NAT | 缬氨酸 | - | SM | |||
4 | 甲状腺 | NAT | 缬氨酸 | - | SM | PTC | 谷氨酸 | - | |||
PTC | 谷氨酸 | - | 13 | 甲状腺 | NAT | 缬氨酸 | - | wt | |||
5 | 甲状腺 | NAT | 缬氨酸 | 缬氨酸 | SM | PTC | 缬氨酸 | - | |||
PTC | 谷氨酸 | 谷氨酸 | 15 | 甲状腺 | PTC | 谷氨酸 | - | M | |||
6 | 淋巴结 | NAT | 缬氨酸 | - | SM | 16 | 甲状腺 | NAT | 谷氨酸 | 谷氨酸 | GM |
PTC | 谷氨酸 | - | PTC | 谷氨酸 | 谷氨酸 | ||||||
8 | 甲状腺 | NAT | 缬氨酸 | 缬氨酸 | SM | 17 | 甲状腺 | NAT | 缬氨酸 | - | SM |
PTC | 缬氨酸 | 谷氨酸 | PTC | 谷氨酸 | - | ||||||
9 | 甲状腺 | NAT | 缬氨酸 | - | wt | 18 | 甲状腺 | PTC | 缬氨酸 | - | wt |
PTC | 缬氨酸 | - | 19 | 甲状腺 | NAT | 缬氨酸 | - | SM | |||
10 | 甲状腺 | NAT | 谷氨酸 | - | GM | PTC | 谷氨酸 | - | |||
PTC | 谷氨酸 | 谷氨酸 | 20 | 甲状腺 | NAT | 谷氨酸 | - | GM | |||
PTC | 谷氨酸 | - |
[1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
doi: 10.3322/caac.21338 URL |
[2] |
Sherman SI. Thyroid carcinoma[J]. Lancet, 2003, 361(9356):501-511.
doi: 10.1016/s0140-6736(03)12488-9 pmid: 12583960 |
[3] |
Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013[J]. JAMA, 2017, 317(13):1338-1348.
doi: 10.1001/jama.2017.2719 URL |
[4] |
Sipos JA, Mazzaferri EL. The therapeutic management of differentiated thyroid cancer[J]. Expert Opin Pharmacother, 2008, 9(15):2627-2637.
doi: 10.1517/14656566.9.15.2627 URL |
[5] |
Albores-Saavedra J, Henson DE, Glazer E, et al. Chan-ging patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study[J]. Endocr Pathol, 2007, 18(1):1-7.
pmid: 17652794 |
[6] |
O'Neill CJ, Oucharek J, Learoyd D, et al. Standard and emerging therapies for metastatic differentiated thyroid cancer[J]. Oncologist, 2010, 15(2):146-156.
doi: 10.1634/theoncologist.2009-0190 URL |
[7] |
Chen H, Luthra R, Routbort MJ, et al. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy[J]. Mol Cancer Ther, 2018, 17(7):1575-1584.
doi: 10.1158/1535-7163.MCT-17-0871 pmid: 29695638 |
[8] |
Hunt J. Understanding the genotype of follicular thyroid tumors[J]. Endocr Pathol, 2005, 16(4):311-321.
doi: 10.1385/EP:16:4:311 URL |
[9] | Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer[J]. J Clin Endocrinol Metab, 2013, 98(11):E1852-E1860. |
[10] |
Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study[J]. J Clin Endocrinol Metab, 2008, 93(10):3943-3949.
doi: 10.1210/jc.2008-0607 URL |
[11] |
Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications[J]. Endocr Rev, 2007, 28(7):742-762.
doi: 10.1210/er.2007-0007 URL |
[12] |
Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[J]. Ann Surg, 2007, 246(3):466-470.
doi: 10.1097/SLA.0b013e318148563d URL |
[13] |
O'Neill CJ, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer[J]. Surgery, 2010, 148(6):1139-1145.
doi: 10.1016/j.surg.2010.09.005 URL |
[14] |
Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentia-ted papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane[J]. Endocr Relat Cancer, 2006, 13(1):257-269.
doi: 10.1677/erc.1.01119 URL |
[15] |
Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism[J]. J Clin Endocrinol Metab, 2007, 92(7):2840-2843.
doi: 10.1210/jc.2006-2707 URL |
[16] |
Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer[J]. Nature, 2004, 431(7007):461-466.
doi: 10.1038/nature02924 URL |
[17] |
Xue X, Zeng N, Gao Z, et al. Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR[J]. Lab Invest, 2015, 95(1):113-120.
doi: 10.1038/labinvest.2014.136 URL |
[18] |
Pan LX, Diss TC, Peng HZ, et al. Clonality analysis of defined B-cell populations in archival tissue sections usi-ng microdissection and the polymerase chain reaction[J]. Histopathology, 1994, 24(4):323-327.
pmid: 8045521 |
[19] |
Nanda SK, Venigalla RK, Ordureau A, et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity[J]. J Exp Med, 2011, 208(6):1215-1228.
doi: 10.1084/jem.20102177 URL |
[20] |
Takano T, Sumizaki H, Nakano K, et al. Increased expression of CD44 variants in differentiated thyroid cancers[J]. Jpn J Cancer Res, 1996, 87(12):1245-1250.
pmid: 9045959 |
[21] |
Orian-Rousseau V, Chen L, Sleeman JP, et al. CD44 is required for two consecutive steps in HGF/c-Met signa-ling[J]. Genes Dev, 2002, 16(23):3074-3086.
doi: 10.1101/gad.242602 URL |
[22] |
Samant RS, Clark DW, Fillmore RA, et al. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation[J]. Mol Cancer, 2007, 6:6.
doi: 10.1186/1476-4598-6-6 URL |
[23] |
Bourguignon LY, Shiina M, Li JJ. Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression[J]. Adv Cancer Res, 2014, 123:255-275.
doi: 10.1016/B978-0-12-800092-2.00010-1 pmid: 25081533 |
[24] |
Misra S, Hascall VC, Berger FG, et al. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer[J]. Connect Tissue Res, 2008, 49(3):219-224.
doi: 10.1080/03008200802143356 URL |
[25] |
Sacks JD, Barbolina MV. Expression and Function of CD44 in Epithelial Ovarian Carcinoma[J]. Biomolecules, 2015, 5(4):3051-3066.
doi: 10.3390/biom5043051 URL |
[26] |
Fan Z, Cui H, Xu X, et al. MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3[J]. Oncotarget, 2015, 6(28):25266-25280.
doi: 10.18632/oncotarget.4457 URL |
[27] |
Schmidt BA, Rose A, Steinhoff C, et al. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors[J]. Cancer Res, 2001, 61(10):4214-4221.
pmid: 11358847 |
[28] |
Bartkova J, Thullberg M, Slezak P, et al. Aberrant expression of G1-phase cell cycle regulators in flat and exo-phytic adenomas of the human colon[J]. Gastroenterology, 2001, 120(7):1680-1688.
pmid: 11375949 |
[29] |
Shan YS, Hsu HP, Lai MD, et al. Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer[J]. Oncol Lett, 2017, 14(4):4517-4526.
doi: 10.3892/ol.2017.6736 URL |
[30] |
Khanna V, Eide CA, Tognon CE, et al. Recurrent cyclin D2 mutations in myeloid neoplasms[J]. Leukemia, 2017, 31(9):2005-2008.
doi: 10.1038/leu.2017.195 pmid: 28630439 |
[31] |
Wang L, Cui Y, Zhang L, et al. The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features[J]. PLoS One, 2016, 11(9):e0161859.
doi: 10.1371/journal.pone.0161859 URL |
[32] |
Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J]. Cancer Res, 2003, 63(7):1454-1457.
pmid: 12670889 |
[33] |
Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma[J]. J Natl Cancer Inst, 2003, 95(8):625-627.
doi: 10.1093/jnci/95.8.625 URL |
[34] |
Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer[J]. J Clin Invest, 2005, 115(1):94-101.
doi: 10.1172/JCI23237 URL |
[35] |
Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer[J]. N Engl J Med, 2013, 368(7):623-632.
doi: 10.1056/NEJMoa1209288 URL |
[36] |
Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2005, 90(12):6373-6379.
doi: 10.1210/jc.2005-0987 URL |
[37] | Sabra MM, Dominguez JM, Grewal RK, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases[J]. J Clin Endocrinol Metab, 2013, 98(5):E829-E836. |
[38] | COSMIC. Complete Data for Gene-ALK[DB/OL]. [2019-05-17]. https://cancer.sanger.ac.uk/cosmic/gene/samples?all_data=&coords=AA%3AAA&dr=&end=1621&gd=&id=50&ln=ALK&mut_pie1=CzG&seqlen=1621&src=gene&start=1. |
[39] | Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated carcinogenesis[J]. Biochim Biophys Acta, 2012, 1823(4):850-860. |
[40] |
Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors[J]. Ann Oncol, 2014, 25(3):552-563.
doi: S0923-7534(19)34258-9 pmid: 32018766 |
[41] |
Kelleher FC, O'Sullivan H, Smyth E, et al. Fibroblast growth factor receptors, developmental corruption and malignant disease[J]. Carcinogenesis, 2013, 34(10):2198-2205.
doi: 10.1093/carcin/bgt254 pmid: 23880303 |
[42] | COSMIC. Complete Data for Gene-FGFR3[DB/OL]. [2019-05-17]. https://cancer.sanger.ac.uk/cosmic/gene/samples?all_data=&coords=AA%3AAA&dr=&end=807&gd=&id=9&ln=FGFR3&mut_pie1=AzG&seqlen=807&src=gene&start=1. |
[43] | My Cancer Genome. KIT[DB/OL]. [2019-05-17]. https://www.mycancergenome.org/content/gene/kit/. |
[44] |
Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor[J]. J Clin Oncol, 2003, 21(23):4342-4349.
pmid: 14645423 |
[45] |
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science, 1998, 279(5350):577-580.
doi: 10.1126/science.279.5350.577 pmid: 9438854 |
[46] | NCBI ClinVar. NM_000222.2(KIT):c.1648_1674del27 (p.Lys550_Lys558del) Variation Report[DB/OL]. [2019-05-17]. https://www.ncbi.nlm.nih.gov/clinvar/variation/13857/. |
[47] |
Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors[J]. Cancer Treat Rev, 2016, 42:47-55.
doi: 10.1016/j.ctrv.2015.11.003 pmid: 26678514 |
[48] | My Cancer Genome. MYC[DB/OL]. [2019-05-17]. https://www.mycancergenome.org/content/gene/myc/. |
[49] | NCBI ClinVar. NM_002467.5(MYC):c.218C>T (p.Thr73Ile) Variation Report[DB/OL]. [2019-05-17]. https://www.ncbi.nlm.nih.gov/clinvar/variation/376300/. |
[50] |
Han B, Cui H, Kang L, et al. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway[J]. Tumour Biol, 2015, 36(8):6295-6304.
doi: 10.1007/s13277-015-3315-4 URL |
[1] | 万颖蕾,彭奕冰,赵缜,樊建萌,季育华. HCMVpp65抗原和IgM抗体检测诊断儿童HCMV活动性感染的比较[J]. 诊断学理论与实践, 2004, 3(05): 41-42+46. |
[2] | 郑岚,黄宇闻,莫琴,王迅,许莉萍,陆萍,凌冰,钱开诚,曹文俊. 运用FQ-PCR技术监测亚甲蓝光化学法对血浆丙型肝炎病毒的灭活效果[J]. 诊断学理论与实践, 2002, 1(02): 43-45. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||